Press Releases

Press Releases

Summary Toggle PDL BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference

INCLINE VILLAGE, Nev. , Nov. 19, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that management will present at the Piper Jaffray Healthcare Conference in New York City. The session will be webcast live and will occur on Tuesday, November 27, 2018 , at

Nov 19, 2018
Summary Toggle PDL BioPharma Reports Third Quarter 2018 Financial Results

Announces CEO succession plan INCLINE VILLAGE, Nev. , Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and nine months ended September 30, 2018 including: Third Quarter Financial Highlights Total revenues of $67.9

Nov 6, 2018
Summary Toggle PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018

INCLINE VILLAGE, Nev. , Oct. 31, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018 , on Tuesday, November 6, 2018 , after market close. PDL's management

Oct 31, 2018
Summary Toggle PDL BioPharma Names Edward Imbrogno Vice President of Finance

INCLINE VILLAGE, Nev. , Oct. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position. Mr. Imbrogno brings to PDL more than 30 years of public accounting and financial reporting experience and will

Oct 8, 2018
Summary Toggle PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

INCLINE VILLAGE, Nev. , Sept. 26, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York City. The session will be webcast

Sep 26, 2018
Summary Toggle PDL BioPharma Announces New $100 Million Stock Repurchase Program

INCLINE VILLAGE, Nev. , Sept. 24, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock. Purchases may be made in open-market transactions, in block

Sep 24, 2018
Summary Toggle PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference

INCLINE VILLAGE, Nev. , Aug. 30, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will present at the H.C. Wainwright 20 th Annual Global Investment Conference next week in New York City. The session

Aug 30, 2018
Summary Toggle PDL BioPharma Reports Second Quarter 2018 Financial Results

INCLINE VILLAGE, Nev. , Aug. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) reports financial results for the three and six months ended June 30, 2018 including: Second Quarter Financial Highlights Total revenues of $46.6 million .

Aug 8, 2018
Summary Toggle PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products

INCLINE VILLAGE, Nev. , Aug. 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the "Royalty Agreement") with Depomed, Inc. (" Depomed ") under which PDL acquired all of Depomed's remaining rights to royalties and

Aug 2, 2018
Summary Toggle PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018

INCLINE VILLAGE, Nev. , Aug. 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30, 2018 , on Wednesday, August 8, 2018 , after market close. PDL's

Aug 1, 2018
Summary Toggle Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors

INCLINE VILLAGE, Nev. , June 22, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced today that retired Eli Lilly and Company executive Elizabeth G. O'Farrell has been named to the Company's Board of Directors, effective June 22, 2018 and increasing the

Jun 22, 2018
Summary Toggle Shlomo Yanai Elected to PDL BioPharma's Board of Directors

INCLINE VILLAGE, Nev. , June 11, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced that at its 2018 annual meeting of stockholders held June 8, 2018 , the Company's stockholders elected Shlomo Yanai to the Company's Board of Directors. The Company

Jun 11, 2018
Summary Toggle PDL BioPharma Names Dr. Jill Jene Vice President, Business Development

INCLINE VILLAGE, Nev. , May 21, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announces the appointment of Jill M. Jene , Ph.D. as Vice President, Business Development . Dr. Jene will lead the efforts to add healthcare assets to PDL's portfolio of products and

May 21, 2018
Summary Toggle PDL BioPharma to Present at Two Upcoming Investor Conferences

INCLINE VILLAGE, Nev. , May 15, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will present at the following two upcoming investor conferences: UBS Global Healthcare Conference Tuesday, May 22, 2018 at 11:30 a.m. EDT New York City Presenter: John P.

May 15, 2018
Summary Toggle PDL BioPharma Announces First Quarter 2018 Financial Results

INCLINE VILLAGE, Nev. , May 9, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2018 including: Total revenues of $38.5 million for the three months ended March 31, 2018 .

May 9, 2018